Bonus Financial Statements From 2010 to 2024

BONS Stock  ILS 10.60  0.20  1.85%   
Bonus Biogroup financial statements provide useful quarterly and yearly information to potential Bonus Biogroup investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bonus Biogroup financial statements helps investors assess Bonus Biogroup's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bonus Biogroup's valuation are summarized below:
Bonus Biogroup does not presently have any fundamental signals for analysis.
Check Bonus Biogroup financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bonus Biogroup's main balance sheet or income statement drivers, such as , as well as many indicators such as . Bonus financial statements analysis is a perfect complement when working with Bonus Biogroup Valuation or Volatility modules.
  
This module can also supplement various Bonus Biogroup Technical models . Check out the analysis of Bonus Biogroup Correlation against competitors.

Bonus Biogroup Company Shares Outstanding Analysis

Bonus Biogroup's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Bonus Biogroup Shares Outstanding

    
  1.17 B  
Most of Bonus Biogroup's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bonus Biogroup is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, Bonus Biogroup has 1.17 B of shares currently outstending. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The shares outstanding for all Israel stocks is notably lower than that of the firm.

Bonus Biogroup Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bonus Biogroup's current stock value. Our valuation model uses many indicators to compare Bonus Biogroup value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bonus Biogroup competition to find correlations between indicators driving Bonus Biogroup's intrinsic value. More Info.
Bonus Biogroup is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bonus Biogroup by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bonus Biogroup's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Bonus Biogroup Financial Statements

Bonus Biogroup stakeholders use historical fundamental indicators, such as Bonus Biogroup's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bonus Biogroup investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bonus Biogroup's assets and liabilities are reflected in the revenues and expenses on Bonus Biogroup's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bonus Biogroup. Please read more on our technical analysis and fundamental analysis pages.
Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd., formerly known as Oceana Advanced Industries Ltd., was founded in 1981 and is based in Haifa, Israel. BONUS BIOGROUP is traded on Tel Aviv Stock Exchange in Israel.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Bonus Stock

Bonus Biogroup financial ratios help investors to determine whether Bonus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bonus with respect to the benefits of owning Bonus Biogroup security.